{
    "clinical_study": {
        "@rank": "90565", 
        "arm_group": {
            "arm_group_label": "Dabigatran Etexilate", 
            "arm_group_type": "Experimental", 
            "description": "patient to receive a capsule containing 75 mg of dabigatran etexilate"
        }, 
        "brief_summary": {
            "textblock": "The study to be conducted is a prospective,  open label trial. It is designed to evaluate\n      the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran\n      etexilate in patients with chronic kidney disease."
        }, 
        "brief_title": "Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Renal Insufficiency, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Male and female patients aged 18 years and older\n\n          2. Impaired renal function defined as a stable Cockroft-Gault and/or actual creatinine\n             clearance between 15-30 ml/min over the last 3 months before study participation.\n\n          3. The single use of either aspirin or Vitamin K Antagonists\n\n          4. Provision of informed consent.\n\n        Exclusion criteria:\n\n          1. Unstable renal function and Creatinin Clearance <15mL/min\n\n          2. Patients treated with two or more platelet aggregation inhibitors\n\n          3. Use of or indication for therapeutic  heparin\n\n          4. Patients with prosthetic heart valves\n\n          5. Haemorrhagic disorder or bleeding diathesis\n\n          6. Platelet count <100 109/L) at screening or during the last 30 days before screening.\n\n          7. Participation in another drug trial in the last 30 days before screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711853", 
            "org_study_id": "1160.166", 
            "secondary_id": "2011-003081-32"
        }, 
        "intervention": {
            "arm_group_label": "Dabigatran Etexilate", 
            "description": "Dabigatran Etexilate 75mg twice daily", 
            "intervention_name": "Dabigatran Etexilate", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leiden", 
                    "country": "Netherlands"
                }, 
                "name": "1160.166.31001 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Exploratory Study to Investigate the Pharmacokinetics and Effects of DABIgatran Etexilate in Patients With Stable Severe RENAL Disease: DabiRenal", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: Central Committee Research Involving Human Subjects"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)", 
                "safety_issue": "No", 
                "time_frame": "up to 11 days"
            }, 
            {
                "measure": "AUCt,ss  (area under the concentration curve of the analyte in plasma at steady state over a uniform dosing interval)", 
                "safety_issue": "No", 
                "time_frame": "up to 11 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711853"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}